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Summary
We discuss Bayesian approaches to multiple comparison problems, using a
decision theoretic perspective to critically compare competing approaches.
We set up decision problems that lead to the use of FDR-based rules and
generalizations. Alternative definitions of the probability model and the utility
function lead to different rules and problem-specific adjustments. Using a loss
function that controls realized FDR we derive an optimal Bayes rule that is a
variation of the Benjamini and Hochberg (1995) procedure. The cutoff is based
on increments in ordered posterior probabilities instead of ordered p-values.
Throughout the discussion we take a Bayesian perspective. In particular, we
focus on conditional expected FDR, conditional on the data. Variations of
the probability model include explicit modeling for dependence. Variations
of the utility function include weighting by the extent of a true negative and
accounting for the impact in the final decision.
Keywords and Phrases: Decision problems; Multiplicities; False
discovery rate.
1. INTRODUCTION
We discuss Bayesian approaches to multiple comparison problems, using a Bayesian
decision theoretic perspective to critically compare competing approaches. Multi-
ple comparison problems arise in a wide variety of research areas. Many recent
discussions are specific to massive multiple comparisons arising in the analysis of
high throughput gene expression data. See, for example, Storey et al. (2004) and
references therein. The basic setup is a large set of comparisons. Let ri denote the
unknown truth in the i-th comparison, ri = 0 (H0) versus ri = 1 (H1), i = 1, . . . , n.
In the context of gene expression data a typical setup defines ri as an indicator for
gene i being differentially expressed under two biologic conditions of interest. For
each gene a suitably defined difference score zi is observed, with zi ∼ f0(zi) if ri = 0,
and zi ∼ f1(zi) if ri = 1. This is the basic setup of the discussions in Benjamini and
Hochberg (1995); Efron et al. (2001); Storey (2002); Efron and Tibshirani (2002);
Genovese and Wasserman (2002, 2003); Storey et al. (2004); Newton et al. (2004);
Cohen and Sackrowitz (2005) and many others. A traditional approach to address
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the multiple comparison problem in these applications is based on controlling false
discovery rates (FDR), the proportion of false rejections relative to the total num-
ber of rejections. We discuss details below. A similar setup arises in the analysis
of high throughput protein expression data, for example, mass/charge spectra from
MALDI-TOF experiments, as described in Baggerly et al. (2003).
Many other applications lead to similar massive multiple comparison problems.
Clinical trials usually record data for an extensive list of adverse events (AE). Com-
paring treatments on the basis of AEs takes the form of a massive multiple compari-
son problem. Berry and Berry (2004) argue that the hierarchical nature of AEs, with
AEs grouped into biologically different body systems, is critical for an appropriate
analysis of the problem. Another interesting application of multiple comparison
and FDR is in classifying regions in image data. Genovese et al. (2002) propose
an FDR-based method for threshold selection in neuroimaging. Shen et al. (2002)
propose an enhanced procedure that takes into account spatial dependence, specifi-
cally in a wavelet based spatial model. Another traditional application of multiple
comparisons arises in record linkage problems. Consider two data sets, A and B,
for example billing data and clinical data in a clinical trial. The record matching
problem refers to the question of matching data records in A and B corresponding
to the same person. Consider a partition of all possible pairs of data records in A
and B into matches versus non-matches. A traditional summary of a given parti-
tion is the Correct Match Rate (CMR), defined as the fraction of correctly guessed
matches relative to the number of true matches. See, for example, Fortini et al.
(2001, 2002). Another interesting related class of problems are ranking and selec-
tion problems. Lin et al. (2004) describe the problem of constructing league tables,
i.e., reporting inference on ranking a set of units (hospitals, schools, etc.). Lin et al.
explicitly acknowledge the nature of the multiple comparison as a decision problem
and discuss solutions under several alternative loss functions.
To simplify the remaining discussion we will assume that the multiple compari-
son problem arises in a microarray group comparison experiment, keeping in mind
that the discussion remains valid for many other massive multiple comparison. A
microarray group comparison experiment records gene expression for a large num-
ber of genes, i = 1, . . . , n, under two biologic conditions of interest, for example
tumor tissue and normal tissue. For each gene we are interested in the comparison
of the two competing hypotheses that gene i is differentially expressed versus not
differentially expressed. We will refer to a decision to report a gene as differentially
expressed as a discovery (or positive, or rejection), and the opposite as a negative
(fail to reject).
2. FALSE DISCOVERY RATES
Many recently proposed approaches to address massively multiple comparisons are
based on controlling false discovery rates (FDR), introduced by Benjamini and
Hochberg (1995). Let δi denote an indicator for rejecting the i-th comparison,
for example flagging gene i as differentially expressed and let D =
P
δi denote the
number of rejections. Let ri ∈ {0, 1} denote the unknown truth, for example an in-
dicator for true differential expression of gene i. We define FDR = (
P
(1− ri)δi)/D
as the fraction of false rejections, relative to the total number of rejections. The
ratio defines a summary of the parameters (ri), the decisions (δi) and the data (in-
directly, through the decisions). As such it is neither Bayesian nor frequentist. How
we proceed to estimate and/or control it depends on the chosen paradigm. Tradi-
tionally one considers the (frequentist) expectation E(FDR), taking an expectation
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over repeated experiments. This is the definition used in Benjamini and Hochberg
(1995). Applications of FDR to microarray analysis are discussed, among many
others, in Efron and Tibshirani (2002). Storey (2002, 2003) introduces the pos-
itive FDR (pFDR) and the q-value and improved estimators for the FDR. In the
pFDR the expectation is defined conditional on D > 0. Efron and Tibshirani (2002)
show the connection between FDR and the empirical Bayes procedure proposed in
Efron et al. (2001) and the FDR control as introduced in Benjamini and Hochberg
(1995). Genovese and Wasserman (2003) discuss more cases of Bayes-frequentist
agreement in controlling various aspects of FDR. Let pi denote a p-value for testing
ri = 1 versus ri = 0. They consider rules of the type δi = I(pi < t). Controlling
the posterior probability P (ri = 0 | Y, pi = t) is stronger than controlling the ex-
pected FDR for a threshold t. Specifically, let FDR(t) denote FDR under the rule
δi = (pi < t), let qˆ(t) ≈ P (ri = 0 | Y, pi = t) denote an approximate evaluation of
the posterior probability for the i−th comparison, and let Q(t) ≈ E(FDR(t)) denote
an asymptotic approximation of expected FDR. Then q(t) ≤ Q(t). The argument
assumes concavity of the c.d.f. for p-values under the alternative ri = 1. Genovese
and Wasserman (2002) also show an agreement of confidence intervals and credible
sets for FDR. They define the realized FDR process FDR(T ) as a function of the
threshold T and call T a (c, α) confidence threshold if P (FDR(T ) < c) ≥ 1−α. The
probability is with respect to a sampling model that includes an (unknown) mixture
of true and false hypotheses. The Bayesian equivalent is a posterior credible set,
i.e., controlling P (FDR(T ) ≤ c | Y ) ≤ 1 − α. Genovese and Wasserman (2003)
show that controlling the posterior credible interval for FDR(T ) is asymptotically
equivalent to controlling the confidence threshold.
Let zi denote some univariate summary statistic for the i-th comparison, for
example a p-value. Many discussions are in the context of an assumed i.i.d. sampling
model for zi, from a mixture model f(·) with terms f0 and f1 corresponding to
subpopulations of differentially and not-differentially expressed genes, respectively:
zi ∼ p0 f0(zi) + (1− p0) f1(zi) ≡ f(zi).
Using latent indicators ri ∈ {0, 1} introduced earlier, the mixture is equivalent to
the hierarchical model:
p(zi | ri = j) = fj(zi) and Pr(ri = 0) = p0 (1)
Let F0 and F denote the c.d.f. for f0 and f . Efron and Tibshirani (2002) define
FDR for rejection regions of the type {zi ≤ z},
Fdr(z) ≡ p0F0(z)/F (z)
and denote it “Bayesian FDR”. The Bayesian label is justified by the use of Bayes
theorem to find the probability of false discovery given {zi ≤ z}, which they show is
equivalent to the defined Fdr statistic. The probability statement is in the context of
the assumed mixture model, for assumed known f0, f1 and p0. In particular, there is
no learning about p0. However, using reasonable data-driven point estimates for the
unknown quantities f0, f1 and p0, the Fdr statistic provides an good approximation
for what P (rn+1 = 1 | zn+1 ≤ z, Y ) would be in a full Bayesian model with flexible
priors on f1 and f0. Here and throughout this paper we use Y to generically indicate
the observed data. Efron et al. (2001) introduce local FDR, as
fdr(z) ≡ p0f0(z)/f(z).
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Under the mixture model, and conditioning on f0, f1 and p0, the fdr statistic is the
probability of differential expression, so fdr(z) = Pr(ri = 1 | zi = z, Y, f0, f1, p0).
As before, one can argue that under a sufficiently flexible prior probability model on
f0, f1, p0, reasonable point estimates can be substituted for the unknown quantities,
allowing us to interpret values of fdr as posterior probabilities, without reference to a
specific prior model (subject to identifiability constraints). In the following sections
we argue that posterior inference for the multiple comparison should consider more
structured models. Inference should not stop with the marginal posterior probability
of differential expression. Rules of the type δi = I(zi ≤ z) are intuitive, but not
necessarily optimal. In the context of a full probability model, and assuming a
reasonable utility function, it is straightforward to derive the optimal rule.
Considering frequentist expectations of FDR, i.e., expectations over repeated
sampling, we need to consider expectations over a ratio of random variables. Short
of uninteresting trivial decision rules, the decision δi = δi(Y ) is a function of the
data and appears in both, numerator and denominator of the ratio. The discussion
significantly simplifies under a Bayesian perspective. The only unknown quantity in
FDR =
P
δi(1− ri)/D is the unknown ri in the numerator. Let vi = P (ri = 1 | Y )
denote the marginal posterior probability of gene i being differentially expressed
and define
FDR = E(FDR | Y ) =
X
(1− vi)δi/D. (2)
Newton et al. (2004) consider decision rules that classify a gene as differentially
expressed if vi > γ
∗, fixing γ∗ to achieve a certain pre-set false discovery rate,
FDR ≤ α. Newton et al. (2004) comment on the dual role of vi in decision rules like
δi = I(vi > γ
∗). It determines the decision, and at the same time already reports
the probability of a false discovery as 1− vi for δi = 1 and the probability of a false
negative as vi for δi = 0.
3. POSTERIOR PROBABILITIES ADJUST FOR MULTIPLICITIES
“Posterior inference adjusts for multiplicities, and no further adjustment is re-
quired.” The statement is only true with several caveats. First, the probability
model needs to include a positive prior probability of non-differential expression for
each gene i. Second, the model needs to include a hyperparameter that defines the
prior probability mass for non-differential expression. For example, consider the
mixture model (1), with independence across i, conditional on p0. The statement
requires that p0 be a parameter with a hyperprior p(p0), rather than fixed. Scott
and Berger (2003) discuss the nature of this adjustment and show some examples.
In the context of microarray data analysis, Do et al. (2005) carry out the same sim-
ulation experiment in the context of a mixture model as in (1). Results are shown
in Table 1. The table shows marginal posterior probabilities vi for differential ex-
pression. The nature of the model is such that vi depends on the gene only through
an observed difference score zi, making it meaningful to list vi by observed differ-
ence score zi. The marginal posterior probability of differential expression adjusts
for the multiplicities. If there are many truly negative comparisons, as in the third
row of the table, then the model reduces the marginal probabilities of differential
expression. If on the other hand there are many truly positive comparisons, as in
the first row, then the model appropriately increases the marginal probabilities.
The probability model need not be i.i.d. sampling. Any probability model that
includes a positive prior probability for ri = 0 and ri = 1, i.e., any model that allows
inference on how comparisons between units are true or false leads to a similar
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Observed z scores
p0 -5.0 -4.0 -3.0 -2.0 -1.0 0.0 1.0 2.0 3.0
0.4 1.0 1.0 1.0 0.9 0.5 0.2 0.4 0.9 1.0
0.8 0.9 0.9 0.8 0.4 0.1 0.1 0.1 0.4 0.8
0.9 0.5 0.4 0.3 0.1 0.1 0.0 0.0 0.1 0.3
Table 1: Posterior probabilities of differential expression, as a function of the
observed difference score zi, under three different simulation truths, using
p0 = 0.4 (first row), 0.8 (second row) and 0.9 (third row) for the proportion
of false comparisons. Probabilities vi > 0.4 are marked in bold face.
adjustment. Berry and Hochberg (1999) discuss this perspective. An interesting
probability model is proposed in Gopalan and Berry (1998). They consider the
problem of comparing group means in an ANOVA setup. They introduce a prior
probability model on all possible partitions of matching group means using the
probability model on random partitions that is implied by sampling from a random
probability measure with a Dirichlet process prior.
Berry and Berry (2004) discuss inference for adverse events (AE) in clinical tri-
als, proposing a hierarchical model to address the multiplicity issue. The data are
occurrences of a large set of adverse events reported in a two arm clinical trial com-
paring standard versus experimental therapy. The authors argue that the conclusion
about a set of AEs with elevated occurrence under the experimental therapy should
be different, depending on whether these AEs cluster in the same body system, or
are scattered across different body systems. In the latter case it should be con-
sidered more likely that the reported AEs are due to random occurrence, whereas
in the earlier case it seems more likely that the increased AEs are caused by the
drug. Berry and Berry (2004) develop a three-level hierarchical model with levels
corresponding to AEs, body systems, and the collection of all body systems. The
proposed hierarchical model leads to the desired inference. Due to borrowing of
strength in the hierarchical model AEs that cluster in the same body system lead
to higher posterior probability of an underlying true difference than if the same AE
counts were observed across different body systems.
4. DECISION THEORETIC APPROACHES
In a review of a Bayesian perspective on multiple comparisons Berry and Hochberg
(1999) comment that “finding posterior distributions of parameters is only part of
the Bayesian solution. The remainder involves decision analysis.” Computing pos-
terior probabilities of differential expression only estimates parameters in the prob-
ability model. It does not yet recommend a specific decision about flagging genes
as differentially expressed or not. Reasonable solutions are likely to follow some
notion of monotonicity. All else being equal, genes with higher marginal probability
of differential expression should be more likely to be reported as differentially ex-
pressed. However, differing levels of differential expression, focused interest in some
subsets of genes, and inference about dependence might lead to violations of mono-
tonicity. More importantly, this argument, without refinement, does not provide
the threshold beyond which comparisons should be rejected.
It can be shown (Mu¨ller et al., 2004) that under several loss functions that
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combine false negative and false discovery counts and/or rates the optimal decision
rule is of the following form. Recall that δi is an indicator for the decision to report
gene i as differentially expressed and vi = Pr(ri = 1 | Y ) denotes the marginal
posterior probability of differential expression for gene i. The optimal decision is
to declare all genes with marginal probability beyond a threshold as differentially
expressed:
δ∗i = I(vi > t). (3)
The choice of loss function determines the specific threshold. In Mu¨ller et al. (2004)
we consider four alternative loss functions. Similar to FDR we define FD =
P
(1−
ri)δi and FN =
P
ri(1 − δi) as the false positive and false negative counts, and
FNR = FN/(n − D) as the false negative ratio. We use FD, FN and FNR for
the posterior expectations. All are easily evaluated. For example, FN =
P
vi(1 −
δi). Considering various combinations of these statistics we define alternative loss
functions. Since the posterior expectation is straightforward, we specify the loss
functions already as posterior expected loss. The first two loss functions are linear
combinations of the false negative and positive counts and ratios. We define
LN (δ, z) = cFD+ FN, (4)
and LR(δ, z) = cFDR + FNR. The loss function LN is a natural extension of
(0, 1, c) loss functions for traditional hypothesis testing problems (Lindley, 1971).
From this perspective the combination of error rates in LR seems less attractive.
The loss for a false discovery and false negative depends on the total number of
discoveries or negatives, respectively. Genovese and Wasserman (2002) interpret c
as the Lagrange multiplier in the problem of minimizing FNR subject to a bound on
FDR. They compare the Benjamini and Hochberg (1995) rule (BH) and the optimal
rule under LR and show that BH almost achieves the optimal risk, in particular for
a large fraction of true nulls.
Alternatively, we consider bivariate loss functions that explicitly acknowledge
the two competing goals:
L2R(δ, z) = (FDR,FNR), L2N (δ, z) = (FD,FN).
We need to define the minimization of the bivariate functions. A traditional ap-
proach to select an action in multicriteria decision problems is to minimize one
dimension of the loss function while enforcing a constraint on the other dimensions
(Keeney et al., 1976). We thus define the optimal decisions under L2N as the mini-
mization of FN subject to FD ≤ αN . Similarly, under L2R we minimize FNR subject
to FDR ≤ αR.
Under all four loss functions the optimal rule is of the form (3). See Mu¨ller et al.
(2004) for a statement of the optimal cutoffs t. The result is true for any probability
model with non-zero prior probability for differential and non-differential expression.
In particular, the probability model could include dependence across genes.
One of the assumptions underlying these loss functions is that all false negatives
are equally undesirable, and all false positives are equally undesirable. This is inap-
propriate in most applications. A false negative for a gene that is truly differentially
expressed, but with a small difference across the two biologic conditions, is surely
less of a concern than a false negative for a gene that is differentially expressed with
a large difference. The large difference might make it more likely that follow up
experiments will lead to significant results. Assume now that the probability model
http://biostats.bepress.com/jhubiostat/paper115
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includes for each gene i a parameter mi that can be interpreted as the level of dif-
ferential expression, with mi = 0 if ri = 0, and mi > 0 if ri = 1. For example, in
the hierarchical gamma/gamma model proposed in Newton et al. (2001) this could
be the absolute value of the log ratio of the gamma scale parameters that index
the sampling distributions under the two biologic conditions. A log ratio of mi = 0
implies equal sampling distributions, i.e., no differential expression. In the mixture
of Dirichlet process model of Do et al. (2005), mi would be the absolute value of
the latent variable generated from the random probability measure with Dirichlet
process prior. A natural extension of the earlier loss functions is to
Lm(m, δ, z) = −
X
δimi + k
X
(1− δi)mi + cD.
A similar weighting with the relative magnitude of errors is underlying Duncan’s
(1965) multiple comparison procedure. Since ri = 0 implies m = 0, the summations
go only over all true positives, ri = 1. The loss function includes a reward propor-
tional to mi for a correct discovery, and a penalty proportional to mi for each false
negative. The last term encourages parsimony, without which the optimal decision
would be to trivially flag all genes. Straightforward algebra shows that the optimal
decision is similar to (3). Let mi = E(mi | Y ) denote the posterior expected level
of differential expression for gene i. The optimal rule is
δ∗i = I{mi ≥ c/(1 + k)} :
Flag all genes with mi greater than a fixed cutoff. The optimal rule remains essen-
tially the same if we replace mi in the loss function by some function of m, allowing
in particular for the loss to be a non-linear function of the true level of differential
expression.
Lf (m, δ, z) = −
X
δifD(mi) +
X
(1− δi)fN (mi) + cD. (5)
The functions fD(m) and fN (m) would naturally be S-shaped, monotone functions
with a minimum at m = 0, and perhaps level off for large levels of m. Let fNi =
E(fN (m) | Y ) denote the posterior expectation for fN (mi), and similarly for fD.
The optimal decision is
δ∗f = I{fDi + kfNi > c}.
Flag all genes with sufficiently large expected reward for discovery and/or penalty
for a false negative. The rule δ∗f follows from the fact that the choice of mi in Lm
was arbitrary.
The introduced loss functions are all generic in the sense of being reasonable loss
functions without reference to a specific decision related to the multiple comparisons.
If the goal of the inference is a very specific decision with a clearly recognizable
implication, a problem-specific loss function should be used as the relevant criterion
for the multiple comparison. For example, Lin et al. (2004) and Shen and Louis
(1998) consider the problem of ranking units like health care providers. Ranking
is a specific form of a multiple comparison problem. It could be described as all
pairwise comparisons, subject to transitivity. They introduce loss functions that
formalize the implications of a specific ranking, relative to the true ranks, and show
the optimal rules for several such loss functions.
Hosted by The Berkeley Electronic Press
8 Mu¨ller, Parmigiani & Rice
Example 1: Epithelial Ovarian Cancer (EOC)
Wang et al. (2004) report a study of epithelial ovarian cancer (EOC). The goal
of the study is to characterize the role of the tumor microenvironment in EOC.
To this end the investigators collected tissue samples from patients with benign
and malignant ovarian pathology. Specimens were collected, among other sites,
from peritoneum adjacent to the primary tumor. RNA was co-hybridized with
reference RNA to a custom-made cDNA microarray including a combination of the
Research Genetics RG HsKG 031901 8k clone set and 9,000 clones selected from
RG Hs seq ver 070700. A complete list of genes is available at
http://nciarray.nci.nih.gov/gal files/index.shtml
(The array is listed as custom printing Hs-CCDTM-17.5k-1px).
We focus on the comparison of 10 peritoneal samples from patients with benign
ovarian pathology versus 14 samples from patients with malignant ovarian pathol-
ogy. The raw data was pre-processed using BRB ArrayTool
(http://linus.nci.nih.gov/BRB-ArrayTools.html). In particular, spots with min-
imum intensity less than 300 in both fluorescence channels were excluded from fur-
ther analysis. See Wang et al. (2004) for a detailed description.
We computed probabilities of differential expression using the POE model pro-
posed in Parmigiani et al. (2002). Inference is summarized by marginal probabilities
of differential expression vi. One parameter in the model is interpretable as the level
of differential expression. Briefly, the basic POE model includes a trinary indicator
eit for gene i and sample t, with eit ∈ {−1, 0, 1} for under-expression, normal and
over-expression. In a variation of the original POE model we use a probit prior
for eit. The probit prior includes a regression on an indicator for malignant ovar-
ian pathology. We denote the corresponding coefficient in the model by mi, and
interpret it as the level of differential expression for gene i. The original model
does not include a gene-specific parameter ri that can be interpreted as differential
expression for gene i. We define ri = I(|mi| > ), using  = 0.5. Figure 1 shows
the selected lists of reported genes under the loss functions LN and Lm (marked
LN and Lm). To facilitate the comparison we calibrated the tradeoff parameter c
in both loss functions to fix D = 20. The difference in the two solutions are related
to the difference between statistical significance and biologic significance. Because
of varying precisions, it is possible that a gene with a very small level of differential
expression reports a high posterior probability of differential expression, and vice
versa.
5. APPROXIMATING BENJAMINI AND HOCHBERG’S RULE
The earlier introduced loss functions and the corresponding Bayes rules control
various aspects of false discovery and false negative counts and rates. While similar
in spirit, the rules are different from methods that have been proposed to control
frequentist expected FDR, for example the rule defined in Benjamini and Hochberg
(1995), henceforth BH.
It is not possible to justify BH (applied to the sorted p-values) as an optimal
Bayes rule under a loss function that includes a combination of FD(R) and FN(R).
This is shown in Cohen and Sackrowitz (2005) and extended in Cohen and Sack-
rowitz (2006). BH can be described as a step-up procedure that compares ordered
observed difference scores z(i) with pre-determined critical cutoffs Ci. Let j denote
the smallest integer i with z(i) > Ci. All comparisons with difference scores beyond
z(j) are rejected. Cohen and Sackrowitz (2005) show that such rules are inadmissi-
ble. The discussion includes a simple example that makes the inadmissibility easily
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interpretable. Consider a set of (ordered) p-values p(i) with p(i) = n
α
n
− , i.e., all
equal values. In particular, the largest p-value, p(n), falls below the BH bound-
ary (j α)/n. The BH rule would lead us to reject all comparisons. Now consider
p(i) = i
α
n
+ . The p-values p(i), i = 1, . . . , n− 1 are substantially smaller, and p(n)
is only slightly larger. Yet, we would be lead not to reject any comparison.
But interestingly, it is possible to still mimic the mechanics of the popular BH
method as the Bayes rule under a specific loss function. The rule replaces the p-
values with increments in posterior probabilities. The correspondence is not exact,
and can not be in the light of Cohen and Sackrowitz’ inadmissibility results.
Recall that δi(z) ∈ {0, 1} denotes the decision rule for the i-th comparison,
ri ∈ {0, 1} is the (unknown) truth, vi = Pr(ri = 1 | Y ) are the marginal posterior
probabilities, FD =
P
δi(1− ri) are the false discovery count, FD =P δi(1− vi) =
E(FD | Y ), and D =P δi is the number of rejections. Let wi = 1 − vi denote the
marginal probability of the i-th null model.
Consider the loss function `B(δ, z, r) = I(FD > αD) − gD, with a monotone
reward gD for the number of discoveries. Marginalizing w.r.t. r, conditional on the
data, we find the expected loss LB(δ, z) = P (FD > αD | Y )− gD. By Chebycheff’s
inequality, P (FD > αD) ≤ FD/(αD). Using this upper bound, we define LB ≈
LU (δ, z) ≡ FD
αD
− gD = FDR/α− gD.
Without loss of generality assume w1 ≤ w2 ≤ w3 . . . are ordered. We show that
under LU with gD = D/n, the optimal decision is to use a threshold equal to the
largest j with (appropriately defined) increment in posterior probability wj less than
(jα)/n. See below for the appropriate definition of increment in wj .
For fixed D, the optimal rule selects the D largest probabilities vi. Let δ
D
i =
I(i ≤ D) denote this rule. To determine the optimal rule we still need to find the
optimal D = j. Consider the condition LU (δ
j , z) ≤ LU (δj−1, z) for preferring δj
over δj−1:
1
αj
jX
i=1
wi − gj ≤ 1
α(j − 1)
j−1X
i=1
wi − gj−1.
After some simplification, and letting wj =
1
j
Pj
i=1 wi denote the average across
comparisons 1 through j, and ∆wj = wj−wj−1, the condition becomes LU (δj , z) <
LU (δ
j−1, z) if ∆wj < (gj − gj−1)αj. A similar condition is true for lag k compar-
isons. Let wij =
1
j−i+1
Pj
h=i wi and ∆wij = wi+1,j − wi.
LU (δ
j , z) ≤ LU (δj−k, z) if ∆wj−k,j ≤ (gj − gj−k)αj/k (6)
The earlier condition was the special case for k = 1. For gj = j/n the condition
becomes ∆wj−k,j ≤ α jn . Condition (6) characterizes the optimal rule δ∗. Let B(2) ≡
1 and B(j) = maxi<j{i : ∆wB(i),i < α in }. In words, B(j) is the best rule δi, i < j.
The optimal rule is δj for
j = max
i

i : ∆wB(i),i ≤ α i
n
ff
.
This characterizes the optimal rule by an algorithm like BH, applied to the incre-
ments in posterior probabilities ∆wB(i),i.
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An alternative justification of a BH type procedure is the following approxima-
tion. Recall that under the loss function LB , the optimal rule must be of the type
δi = I(vi ≥ vj) for some optimal j. If we knew the number n0 of true null hypothe-
ses, then we would find FD ≤ (1−vj)n0, and thus FDR ≤ (1−vj)n0/j. Assume that
the probabilities vi are ordered. To minimize vj , while controlling FDR we would
determine the cutoff by the maximum j with (1 − vj) ≤ jα/n0. Finally, replacing
n0 by the conservative bound n we get a BH type rule on the posterior probabilities
(1− vj).
A fundamental difference of BH and the rule under LU is the use of posterior
probabilities instead of p-values. Of course, the two are not the same. The relation-
ship of p-values and posterior probabilities is extensively discussed, for example, in
Casella and Berger (1987), Sellke et al. (2001) and Bayarri and Berger (2000).
The loss function LB serves to make the use of BH type rules plausible under
an approximate expected loss minimization argument. We would not, however,
recommend it for practical use. Assume we had fantastically good data, with vi ∈
{0, 1}, i.e., we essentially know the truth for all comparisons. The rule δi = I(vi = 1)
that reports the known truth is not optimal. Under LB it can be improved by
knowingly reporting false positives with vi = 0. This is possible since LB rewards
for large D, and only introduces a penalty for false positives if the set threshold αD
is exceeded. A similar statement applies for LU .
6. FDR AND DEPENDENCE
In previous sections we argued for the use of posterior probabilities to account
for multiplicities, and for a decision theoretic approach to multiple comparisons.
The two arguments are not competing, but naturally complement each other. A
structured probability model helps us to identify genes that might be of more interest
than others.
In particular, the dependence structure of expression across genes might be of
interest. If the goal is to develop a panel of biomarkers to classify future samples,
then it is desireable to have low correlation of the expression levels for the reported
set of differentially expressed genes. For other applications one might want to argue
the opposite. Recall the example about inference on adverse events mentioned in
the introduction.
In Mu¨ller and Parmigiani (2006) we introduce a probability model for gene
expression that includes dependence for subsets of genes. The dependent subsets
are typically identified as genes with a common functionality or genes corresponding
to the nodes on a pathway of interest. The probability model allows us to use known
pathways to formulate informative prior probability models for dependence across
genes that feature in that pathway. Alternatively, for a small to moderately large
set of genes the model allows us to learn about dependence starting from relatively
vague prior assumptions. We briefly outline the features of the model that are
relevant for the decision about reporting differentially expressed genes. Dependence
is introduced not on the observed gene expressions, but on imputed trinary indicators
eit ∈ {−1, 0, 1} for under- and over-expression of gene i in sample t. We build on the
POE model introduced in Parmigiani et al. (2002), and already briefly mentioned
earlier. In a variation of the basic POE model, in Mu¨ller and Parmigiani (2006)
we represent the probabilities for the trinary outcome by a latent normal random
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variable zit, with
eit =
8><>:
−1 if zit < −1
0 if − 1 < zit < 1
1 if zit > 1.
(7)
The latent variables zit are continuous random variables that allow us to introduce
the desired dependence on related genes, as well as a regression on biologic condition.
Let xt denote a sample-specific covariate vector including an indicator xt1 for the
biologic condition of the sample t and other sample-specific covariates. For example,
in the case of a two group comparison between tumor and normal tissues, xt1 could
be a binary indicator of tumor. Also, let {ejt; j ∈ Ni} denote the trinary indicators
for other genes that we wish to include as possible parent nodes in the dependent
prior model for zit. We assume a regression
zit = g(xt, ejt, j ∈ Ni) + i, (8)
with mean function g(·) and standard normal residuals i. The regression on ejt
introduces the desired dependence, and the regression on xt includes the regression
on the biologic condition xt1, as before. Let mi denote the regression coefficient for
xt1, the biologic condition. Also, define Σ1 as the correlation matrix of {zit; δi = 1},
the latent scores corresponding to the reported genes. The model allows us to include
a term in the loss function that penalizes the reporting of highly correlated genes.
We modify Lf to
LD(m, δ, z) = −k1 log(|Σ1|)−k2
X
δifD(mi)+k3
X
(1−δi)fN (mi)+k4 cD. (9)
The loss function encourages the inclusion of few highly differentially expressed genes
with low correlation. Correlation is formalized as the tetrachoric correlation of the
trinary outcomes eit. See, for example, Ronning and Kukuk (1996) for a discussion
of polychoric correlations for ordinal outcomes.
Example 1 (ctd): Epithelial Ovarian Cancer (EOC)
Earlier we reported inference using the POE model and the loss functions LN and
Lm. We reanalyze the data with a variation of the POE model that includes depen-
dent gene expression. In the implementation we specified (9) with k1 = 1, k2 = 0.01,
k3 = k4 = 0, restricting to D = 20 (for comparability with the results under LN
and Lm), and setting fD(mi) = m
2
i . The inference summaries vi and mi change
slightly when adjusting for dependence. The change in the estimates is shown in
Figure 1. Although the changes are minimal for most genes, the impact in the final
decision is visible. The first four rows of Figure 2 show the reported set of genes
under LN using the independent POE model (row 1) versus the dependent model
(row 2), under Lm using the independent (row 3) and dependent (row 4) model.
The last row shows inference under the loss function LD.
7. A PREDICTIVE LOSS FUNCTION
Microarray experiments are often carried out as hypothesis generating experiments,
to screen for promising genes to be followed up in later experiments. Abruzzo
et al. (2005) describe a setup, using RT-PCR to validate a list of differentially
expressed genes found in a microarray group comparison experiment. In particular,
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Figure 1: Inference with dependent prior (y-axis) vs. indep prior (x-
axis). The changes are large enough to change the decisions.
Figure 2: Genes with δi = 1, using LN (top), LN and dep model, Lm,
Lm and dep model, and LD (bottom).
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they use TaqMan Low-Density Arrays for real-time RT-PCR (Applied Biosystems,
Foster City, USA). They consider inference for nine samples from patients with
chronic lymphocytic leukemia (CLL), using the microarray experiment for a first
step screening experiment, and the real-time RT-PCR to validate the identified
genes. With a setup like this experiment in mind we define a utility function that is
based on the success of a future followup study. To define the desired loss function
we need to introduce some more detail of a joint probability model for the microarray
and real time RT-PCR experiments. Eventually we will use a stylized description
of inference in this model to define a loss function.
Let zit be a suitably normalized measurement for gene i in sample t, with ap-
proximately unit marginal variance, var(zit) ≈ 1. For example, zit could be the
latent probit score in (7). Let yit denote the recorded outcome of the RT-PCR for
gene i in sample t. The data are copy numbers, interpreted as base two logarithm of
the relative abundance of RNA in the sample. Abruzzo et al. (2005) use a normal
linear mixed effects model to calibrate the raw data against a calibrator sample and
an endogenous control, chosen to reduce the variance of corrected responses across
samples. Let yit denote the calibrated pre-processed data. An important conclu-
sion of the discussion in Abruzzo et al. (2005) is inference about the correlation of
the microarray and RT-PCR measurements. They find a bimodal distribution of
correlations across genes. About half the genes show a cross-platform correlation
ρi ≈ 0.8, and half show essentially zero correlation, ρi = 0.
We introduce a simple hierarchical model to represent the critical features of the
cross-platform dependence, and a realistic distribution of the RT-PCR outcomes.
We build on the POE model described earlier, in (7) and (7), without necessarily
including the dependent model extension. Let zit denote the latent score in (7). For
yit we assume:
p(yit | zit, ρi) =
(
zit with prob. ρi
N(0, 1) with prob. (1− ρi) (10)
with Pr(ρi = ρ
?) = pρ and Pr(ρi = 0) = 1 − pρ. We use ρ? = 0.8 and pρ = 0.5 to
approximately match the reported inference in Abruzzo et al. (2005). Also, after
standardization Abruzzo et al. (2005) found standard deviations in the RT-PCR
outcomes for each gene across samples in the range of approximately 0.5 through
1.5 (with some outliers below and above). We chose the unit variance in the normal
term above to match the order of magnitude of these reported standard deviations.
Consider now the problem of reporting a list of differentially expressed genes in
a microarray group comparison experiment. We assume that the selected genes will
be validated in a future followup real-time RT-PCR experiment, using, for example,
the described TaqMan Low-Density Arrays. We build a loss function designed to
help us to construct a rule that identifies genes that are most likely to achieve a
significant result in the followup experiment. For a stylized description we assume
that the followup experiment is successful for gene i if we can report a statistically
significant difference of expression across the two biologic conditions.
In words, the construction of the proposed loss function proceeds as follows.
For each identified gene i we first select an alternative hypothesis. We then carry
out a sample size argument based on achieving a desired power for this alternative
versus the null hypothesis of no differential expression, using a traditional notion of
power. Next we find the posterior predictive probability of a statistically significant
outcome (Ri) for the future experiment. Finally, we define a loss function with
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terms related to the posterior predictive probability for Ri and the sampling cost
for the future experiment. The stylized description is not a perfect reflection of
the actual experimental process. It is not even a reasonable model for actual data
analysis. But we believe it captures the critical features related to the desired
decision of identifying differentially expressed genes. In particular, it includes a
natural correction of statistical significance for the size of the effect.
Let xt ∈ {−0.5, 0.5} denote a (centered) indicator for the biologic condition of
sample t. Recall from (7) that the level of differential expression for gene i, mi, was
defined as the probit regression coefficient for an indicator of the biologic condition.
Let (mi, si) denote the posterior mean and standard deviation of mi. Let ρ = pρρ
?
denote the assumed average cross-platform correlation, averaged across genes. Let
µi1 = E(yit | xt > 0) and µi0 = E(yit | xt < 0) denote the mean expression
under the two conditions in the followup experiment. For the upcoming sample size
argument we assume a test of the null hypothesis H0 : µi1 − µi0 = 0 versus the
alternative hypotheses H1 : µi1 − µi0 = m∗yi, with m∗yi = ρ(mi − si), the mean
difference under an assumed alternative mi = mi − si. Let qα denote the (1 − α)
quantile of a standard normal distribution. Assuming that upon conclusion of the
followup experiment the investigators carry out a normal z-test, we find a required
sample size
ni(z) ≥ 2
ˆ
(qα + qβ)/m
∗
yi
˜2
for a given significance level α and power (1 − β). The sample size is a function
of the data z, implicitly through the choice of the alternative m∗yi. Here sample
size refers to the number of samples under each biologic condition, i.e., the total
number of samples is 2n. Let yi0 and yi1 denote the sample average in the followup
experiment, for gene i and the two conditions. Let Ri = {(yi1 − yi0)
p
n/2 ≥ qα}
denote the event of a statistically significant difference for gene i in the followup
experiment. Let pii = Pr(Ri | Y ) denote the posterior predictive probability of Ri.
Let Φ(·) denote the standard normal c.d.f.
pii(z) = (1− pρ)α+ pρΦ
24ρ?mi1pni/2− qαq
1 + n
2
ρ∗2s2i
35 .
Combining ni and pii to trade off the competing goals of small sampling cost and
high success probability we define a loss function
LF (δ, z) =
X
δi=1
[−c1pii(z) + ni(z)] + c2D (11)
Under the loss function LF , the optimal rule is easily seen as
δ∗i = I(ni + c2 ≤ c1pii).
If we replace classical power by Bayesian power (Spiegelhalter et al., 2004, chapter
6.5.3) then pii remains constant by definition, leaving only the bound on the sample
size ni. Also, c2 could be zero if the size of the reported short-list is not an issue.
Figure 3 shows the optimal decision under LF for the EOC example (squares).
We used c1 = 3000 and calibrated c2 such that the optimal decision reports D =
20 genes, as before. The value for c1 was chosen to have the reward c1 match
approximately 10 times the average sampling cost of a followup trial.
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8. SUMMARY
Table 2 summarizes the proposed loss functions and rules. For all except LD the op-
timal rule can be described as a threshold for an appropriate gene-specific summary
statistic of the data. Storey (2005) describes such rules as significance thresholding.
The summaries are the marginal posterior probability of differential expression vi,
posterior mean and standard deviation of the level of differential expression (mi, si),
the sample size for a followup experiment ni, the posterior predictive probability of a
significant outcome pii, and the increment in posterior probability of non-differential
expression ∆wB(i),i. The last three are functions of (vi,mi, si) only.
Table 2: Alternative loss functions and optimal rules
Loss function Rule
LN = cFD+ FN δi = I(vi > t)
Lm = −
∑
δimi + k
∑
(1− δi)mi + cD δi = I(mi > t)
LD = −k1 log(|Σ1|)− k2
∑
δifD(mi)+
+k3
∑
(1− δi)fN (mi) + k4D no closed form
LF =
∑
δi=1
(−c1pii + ni) + c2D δi = I(ni + c2 ≤ c1pii)
LU = FDR/α− g(D) δi = I(vi ≥ vj) with
j = maxi
{
i : ∆wi,B(i) ≤ α i/n
}
In summary, all optimal rules are computed on the basis of only a few under-
lying summaries. This makes it possible to easily consider multiple rules in a data
analysis. Critical comparison of the resulting rules leads to a finally reported set of
comparisons. In some cases the application leads to a different loss function. Good
examples are the loss functions considered in Lin et al. (2004). If a specific loss
function arises from a specific case study, it should be used.
The loss function LD requires the additional summary Σ1(δ). Let S denote a
covariance matrix of the relevant latent variables for all genes that are considered for
reporting in LD. The desired Σ1(δ) for any subset of selected genes is then computed
as the marginal correlation matrix for that subset. Let Sδ denote the submatrix
defined by choosing rows and columns selected by δ. Let λi = 1/
√
Sii, and λδ denote
the vector of λi corresponding to the reported genes. We use Σ1(δ) = λδ[Sδ]λ
′
δ. This
reduces δD to a function of m and S only.
Figure 3 compares the reported gene lists for the loss functions LN , Lm and
LD, under the independent model and the dependent model. For many genes the
decision remains unchanged across all loss functions. For some genes with high
probability of differential expression, but small level of differential expression, and
vice versa, the decision depends on whether or not the terms in the loss function
are weighted by mi.
9. DISCUSSION
We have reviewed alternative approaches to addressing problems related to massive
multiple comparisons. Starting from traditional rules that control expected FDR,
with the expectation over repeated sampling, we have discussed the limitation of the
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Figure 3: Comparison of optimal rules for LN (circles) under the
independent model (black) and dependent model (light gray), Lm (triangle)
under the independent (black) and dependent model (gray), and LF (square).
For each gene (horizontal axis) symbols are plotted against the rank of the
corresponding significance threshold statistic (vertical axis). The reported
genes under each rule are the top 20 ranked genes (above the dashed horizontal
line). The symbols corresponding to selected genes are filled. The names of
selected genes are shown on the vertical axis. Genes are sorted by average
rank under the five criteria.
interpretation of these decisions as Bayesian rules. We have argued for a solution
of the massive multiple comparisons as a decision problem, and we have shown how
this is implemented in structured probability models including dependence across
genes. Most, but not all, loss functions lead to rules that can be defined in terms of
a significance thresholding function, S(data), as proposed in Storey (2005).
The proposed approaches are all based on casting the multiple comparison prob-
lem as a decision problem and thus inherit the limitations of any decision theoretic
solution. In particular, we recognize that not all research is carried out to make
a decision. The decision theoretic perspective might be inappropriate when an ex-
periment is carried out for more heuristic learning, without being driven by specific
decisions. Also, all arguments were strictly model-based. Even results that apply for
any probability model still need a specific probability model to implement related
approaches. Like any model-based inference, the implementation involves the often
difficult tasks of prior elicitation, and the choice of appropriate parametric models.
Additionally, our arguments require the choice of a utility function. A common
feature of early stage hypothesis generating experiments is that they serve multiple
needs. We might want to carry out a microarray experiment to suggest interesting
genes and proteins for further investigation, to propose suitable candidates for a
correlation study with clinical outcomes, and also to simply understand molecular
mechanisms.
We caution against over-interpretation of results based on highly structured
probability models and often arbitrary choices of utility functions. Data analysis for
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high-throughput gene expression data is particularly prone to problems arising from
data pre-processing. Often it is more important to understand the pre-processing
of the raw data, and correct it if necessary, than to spend effort on sophisticated
modeling. Specifically related to the dependent probability model, it is important
to acknowledge limitation of pathway information that is used to select the set of
possible parent nodes Ni in (8) when constructing the dependent probability model.
Pathway information does not necessarily describe relations among transcript levels,
although it carries some information about it.
We have focused on the inference problem of reporting lists of differentially
expressed genes, and inference on massive multiple comparisons in general. A similar
framework, using the same probability models and loss functions, can be used for
other decision problems related to the same experiments. For example, one could
consider choosing the sample size for a future experiment (sample size selection),
ranking genes or selecting a fixed set of genes (for a panel of biomarkers).
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